Soru

Zorluk: Çok zorPathology and Biopsy Interpretation

A 52-year-old man presents to the clinic with a 2-year history of progressive, severe proximal muscle weakness, deep bone pain, and multiple atraumatic rib fractures. Laboratory evaluation reveals the following:

Laboratory TestResultReference Range
Serum calcium9.2 mg/dL8.4-10.2 mg/dL
Serum phosphorus1.4 mg/dL2.5-4.5 mg/dL
Alkaline phosphatase285 U/L40-120 U/L
25-hydroxyvitamin D34 ng/mL20-50 ng/mL
Intact PTH45 pg/mL15-65 pg/mL
FGF23450 RU/mL< 180 RU/mL

A whole-body somatostatin receptor PET/CT scan demonstrates an intensely avid, 2.5-cm soft tissue mass in the plantar aspect of his left foot. The patient undergoes a wide local excision of the lesion.

Which of the following pathologic and immunohistochemical findings are characteristic of this patient's most likely diagnosis? (Select all that apply)

  1. The presence of bland, uniform spindle cells embedded in a distinctive 'grungy', basophilic, calcified matrixCevap
  2. Diffuse immunohistochemical expression of fibroblast growth factor 23 (FGF23) and somatostatin receptor 2A (SSTR2A)Cevap
  3. C
    Nuclear expression of STAT6 and widespread CD34 positivity, indicative of a paraneoplastic syndrome driven by insulin-like growth factor 2
  4. D
    Histologic features consistent with a chief cell adenoma, explaining the hypophosphatemia through an ectopic hormone mechanism
  5. E
    A biphasic proliferation of epithelial glandular structures and a uniform spindle cell stroma that strongly expresses TLE1

Cevap

The correct findings include the presence of bland spindle cells in a distinctive 'grungy', basophilic, calcified matrix, as well as diffuse immunohistochemical expression of FGF23 and SSTR2A.
The patient's clinical presentation of hypophosphatemia, markedly elevated FGF23, and severe osteomalacia in the setting of a somatostatin receptor-avid soft tissue mass is diagnostic of tumor-induced (oncogenic) osteomalacia. This paraneoplastic syndrome is most commonly caused by a phosphaturic mesenchymal tumor (PMT). Histologically, PMTs are characterized by a proliferation of bland, uniform spindle cells embedded in a highly distinctive 'grungy' or flocculent basophilic, calcified matrix. Immunohistochemically, they typically show diffuse expression of FGF23 (which confirms the mechanism of renal phosphate wasting) and somatostatin receptor 2A (SSTR2A) (which explains the intense avidity on somatostatin-receptor functional imaging, such as DOTATATE PET scans).

Adım Adım Çözüm

1
Analyze the patient's clinical and laboratory presentation.
The patient has severe bone pain, fractures, isolated profound hypophosphatemia, elevated alkaline phosphatase, and normal calcium and PTH levels.
This specific metabolic profile rules out hyperparathyroidism and primary vitamin D deficiency, pointing directly to isolated renal phosphate wasting.
2
Correlate the metabolic profile with the specific biomarker and functional imaging findings.
The markedly elevated FGF23 level and the presence of a somatostatin receptor-avid soft tissue mass in the foot confirm a diagnosis of tumor-induced (oncogenic) osteomalacia.
FGF23 is a phosphatonin that directly inhibits renal phosphate reabsorption. Its ectopic secretion by a tumor causes this specific paraneoplastic syndrome.
3
Identify the characteristic histopathologic features of the causative neoplasm.
The most common causative tumor is a phosphaturic mesenchymal tumor (PMT), which is characterized histologically by bland spindle cells embedded in a distinctive 'grungy', smudgy, basophilic calcified matrix.
Recognizing this unique and highly specific morphologic appearance is essential for the definitive pathologic diagnosis of a PMT.
4
Determine the confirmatory immunohistochemical profile of the tumor.
PMTs typically demonstrate diffuse, strong positivity for FGF23 and somatostatin receptor 2A (SSTR2A).
Immunohistochemistry confirms the functional nature of the tumor (FGF23 production) and directly correlates with its specific functional imaging avidity (SSTR2A).

Anahtar Kavram

Diagnosis of phosphaturic mesenchymal tumor (PMT) causing oncogenic osteomalacia requires identifying its characteristic histologic finding (grungy calcified matrix) and specific immunohistochemical profile (FGF23 and SSTR2A positivity).
Bu soruyu puanla